{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:17Z","timestamp":1707524477065},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,18]]},"DOI":"10.7759\/cureus.19701","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T14:45:00Z","timestamp":1637246700000},"source":"Crossref","is-referenced-by-count":0,"title":["Seropositive Muscle-Specific Tyrosine Kinase Myasthenia Gravis Presenting as a Late-Onset Isolated Sixth Nerve Palsy: A Case Report and a Brief Review of Subtypes of Myasthenia Gravis"],"prefix":"10.7759","author":[{"given":"Gyusik","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Kesserwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb JP","year":"2014","unstructured":"Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014, 175:408-18. 10.1111\/cei.12217","journal-title":"Clin Exp Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.145987","article-title":"Ocular myasthenia gravis: a review","volume":"62","author":"Nair AG","year":"2014","unstructured":"Nair AG, Patil-Chhablani P, Venkatramani DV, Gandhi RA. Ocular myasthenia gravis: a review. Indian J Ophthalmol. 2014, 62:985-91. 10.4103\/0301-4738.145987","journal-title":"Indian J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26107","article-title":"Myasthenia gravis with muscle-specific tyrosine kinase antibodies: a narrative review","volume":"58","author":"Morren J","year":"2018","unstructured":"Morren J, Li Y. Myasthenia gravis with muscle-specific tyrosine kinase antibodies: a narrative review. Muscle Nerve. 2018, 58:344-58. 10.1002\/mus.26107","journal-title":"Muscle Nerve"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36. 10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.605902","article-title":"Controversies in ocular myasthenia gravis","volume":"11","author":"Evoli A","year":"2020","unstructured":"Evoli A, Iorio R. Controversies in ocular myasthenia gravis. Front Neurol. 2020, 11:605902. 10.3389\/fneur.2020.605902","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou P","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J, et al.. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014, 52:139-45. 10.1016\/j.jaut.2013.12.004","journal-title":"J Autoimmun"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis K","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020, 11:212. 10.3389\/fimmu.2020.00212","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: clinical features and management","volume":"11","author":"Rodolico C","year":"2020","unstructured":"Rodolico C, Bonanno C, Toscano A, Vita G. MuSK-associated myasthenia gravis: clinical features and management. Front Neurol. 2020, 11:660. 10.3389\/fneur.2020.00660","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli A","year":"2018","unstructured":"Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, Marino M. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018, 1412:82-9. 10.1111\/nyas.13518","journal-title":"Ann N Y Acad Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda S","year":"2017","unstructured":"Huda S, Waters P, Woodhall M, et al.. IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurol Neuroimmunol Neuroinflamm. 2017, 4:e357. 10.1212\/NXI.0000000000000357","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera J","year":"2012","unstructured":"D\u00edaz-Manera J, Mart\u00ednez-Hern\u00e1ndez E, Querol L, et al.. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012, 78:189-93. 10.1212\/WNL.0b013e3182407982","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/ajem.2001.28038a","article-title":"Myasthenia gravis presenting as a unilateral abducens nerve palsy","volume":"19","author":"Feuer H","year":"2001","unstructured":"Feuer H, Jagoda A. Myasthenia gravis presenting as a unilateral abducens nerve palsy. Am J Emerg Med. 2001, 19:410-2. 10.1053\/ajem.2001.28038a","journal-title":"Am J Emerg Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/77561-seropositive-muscle-specific-tyrosine-kinase-myasthenia-gravis-presenting-as-a-late-onset-isolated-sixth-nerve-palsy-a-case-report-and-a-brief-review-of-subtypes-of-myasthenia-gravis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:21Z","timestamp":1707507021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/77561-seropositive-muscle-specific-tyrosine-kinase-myasthenia-gravis-presenting-as-a-late-onset-isolated-sixth-nerve-palsy-a-case-report-and-a-brief-review-of-subtypes-of-myasthenia-gravis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.19701","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}